JP2011525191A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011525191A5 JP2011525191A5 JP2011514851A JP2011514851A JP2011525191A5 JP 2011525191 A5 JP2011525191 A5 JP 2011525191A5 JP 2011514851 A JP2011514851 A JP 2011514851A JP 2011514851 A JP2011514851 A JP 2011514851A JP 2011525191 A5 JP2011525191 A5 JP 2011525191A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable composition
- antigen
- cells
- csf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 241000186216 Corynebacterium Species 0.000 claims 1
- 241001464975 Cutibacterium granulosum Species 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 108010074108 interleukin-21 Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 230000001235 sensitizing effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7458208P | 2008-06-20 | 2008-06-20 | |
| US61/074,582 | 2008-06-20 | ||
| PCT/US2009/047987 WO2009155535A2 (en) | 2008-06-20 | 2009-06-19 | Compositions, methods and kits for eliciting an immune response |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015016782A Division JP2015134767A (ja) | 2008-06-20 | 2015-01-30 | 免疫応答を誘発するための組成物、方法およびキット |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011525191A JP2011525191A (ja) | 2011-09-15 |
| JP2011525191A5 true JP2011525191A5 (enExample) | 2012-08-09 |
Family
ID=41434717
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011514851A Pending JP2011525191A (ja) | 2008-06-20 | 2009-06-19 | 免疫応答を誘発するための組成物、方法およびキット |
| JP2015016782A Pending JP2015134767A (ja) | 2008-06-20 | 2015-01-30 | 免疫応答を誘発するための組成物、方法およびキット |
| JP2016249706A Active JP6342982B2 (ja) | 2008-06-20 | 2016-12-22 | 免疫応答を誘発するための組成物、方法およびキット |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015016782A Pending JP2015134767A (ja) | 2008-06-20 | 2015-01-30 | 免疫応答を誘発するための組成物、方法およびキット |
| JP2016249706A Active JP6342982B2 (ja) | 2008-06-20 | 2016-12-22 | 免疫応答を誘発するための組成物、方法およびキット |
Country Status (8)
| Country | Link |
|---|---|
| US (12) | US8425898B2 (enExample) |
| EP (4) | EP4218806A1 (enExample) |
| JP (3) | JP2011525191A (enExample) |
| CN (1) | CN102123732A (enExample) |
| AU (1) | AU2009259923B2 (enExample) |
| CA (1) | CA2728739C (enExample) |
| DK (1) | DK3156069T3 (enExample) |
| WO (1) | WO2009155535A2 (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2155782A2 (en) | 2007-03-26 | 2010-02-24 | Dako Denmark A/S | Mhc peptide complexes and uses thereof in infectious diseases |
| WO2009003493A2 (en) | 2007-07-03 | 2009-01-08 | Dako Denmark A/S | Mhc multimers, methods for their generation, labeling and use |
| WO2009039854A2 (en) | 2007-09-27 | 2009-04-02 | Dako Denmark A/S | Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics |
| DK2254592T3 (da) | 2008-02-28 | 2019-09-09 | Dako Denmark As | MHC-multimerer til Borrelia-diagnostik og sygdom |
| CA2728739C (en) * | 2008-06-20 | 2017-07-11 | Duke University | Use of human cytomegalovirus antigens to enhance immune responses to cancer cells |
| WO2010009735A2 (en) | 2008-07-23 | 2010-01-28 | Dako Denmark A/S | Combinatorial analysis and repair |
| GB0817244D0 (en) | 2008-09-20 | 2008-10-29 | Univ Cardiff | Use of a protein kinase inhibitor to detect immune cells, such as T cells |
| WO2010037402A1 (en) | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| US11992518B2 (en) | 2008-10-02 | 2024-05-28 | Agilent Technologies, Inc. | Molecular vaccines for infectious disease |
| EP3238782A3 (en) * | 2010-04-06 | 2018-01-03 | ExoCyte Therapeutics Pte, LTD | Methods of treating cancer |
| EP2697248B1 (en) * | 2011-04-15 | 2020-03-11 | Nauclér, Cecilia | Genetic variant of cytomegalovirus (cmv) |
| CN102363818B (zh) * | 2011-06-28 | 2013-01-02 | 同昕生物技术（北京）有限公司 | 同时检测人ebv、bkv和 cmv的三重实时荧光定量pcr方法及试剂盒 |
| EP3269388A1 (en) * | 2012-10-30 | 2018-01-17 | Pfizer Inc. | Recombinant particle based vaccines against human cytomegalovirus infection |
| US10106817B2 (en) * | 2013-02-14 | 2018-10-23 | The J. David Gladstone Institutes | Compositions and methods of use thereof for identifying anti-viral agents |
| EP3888675A1 (en) * | 2013-09-24 | 2021-10-06 | Duke University | Compositions, methods and kits for eliciting an immune response |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| WO2015073801A1 (en) | 2013-11-14 | 2015-05-21 | Duke University | Tetanus toxoid and ccl3 improve dc vaccines |
| EP3074770B1 (en) | 2013-11-26 | 2020-04-29 | Duke University | Immune monitoring to predict and prevent infection |
| EP3215165B1 (en) | 2014-11-05 | 2020-12-23 | Memorial Sloan Kettering Cancer Center | Methods of selecting t cell line and donor thereof for adoptive cellular therapy |
| WO2016146143A1 (en) | 2015-03-16 | 2016-09-22 | Amal Therapeutics Sa | Cell penetrating peptides and complexes comprising the same |
| US10746736B2 (en) * | 2015-03-26 | 2020-08-18 | University Of Houston System | Integrated functional and molecular profiling of cells |
| HK1254397A1 (zh) | 2015-06-26 | 2019-07-19 | 纪念斯隆-凯特林癌症中心 | 通过t细胞疗法治疗cmv视网膜炎的方法 |
| EP3364981A4 (en) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
| EP3364949A4 (en) | 2015-10-22 | 2019-07-31 | ModernaTX, Inc. | CANCER VACCINES |
| WO2017096247A1 (en) * | 2015-12-04 | 2017-06-08 | Mayo Foundation For Medical Education And Research | Methods and vaccines for inducing immune responses to multiple different mhc molecules |
| JP7653759B2 (ja) | 2016-01-20 | 2025-03-31 | フェイト セラピューティクス，インコーポレイテッド | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| AU2017210031C1 (en) | 2016-01-20 | 2020-11-26 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| EP3429618B1 (en) | 2016-03-16 | 2024-02-21 | Amal Therapeutics SA | Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine |
| KR20190057345A (ko) | 2016-09-21 | 2019-05-28 | 아말 테라퓨틱스 에스에이 | 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체 |
| CA3037002A1 (en) | 2016-09-23 | 2018-03-29 | Memorial Sloan Kettering Cancer Center | Generation and use in adoptive immunotherapy of stem cell-like memory t cells |
| EP3528821A4 (en) | 2016-10-21 | 2020-07-01 | ModernaTX, Inc. | HUMAN CYTOMEGALOVIRUS VACCINE |
| US11932870B2 (en) | 2016-12-05 | 2024-03-19 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| CA3064375A1 (en) | 2017-05-25 | 2018-11-29 | Memorial Sloan Kettering Cancer Center | Use of the il-15/il-15ra complex in the generation of antigen-specific t cells for adoptive immunotherapy |
| EP3700553A1 (en) | 2017-10-23 | 2020-09-02 | Atara Biotherapeutics, Inc. | Methods of managing tumor flare in adoptive immunotherapy |
| KR20200084883A (ko) * | 2017-11-06 | 2020-07-13 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 기존의 미생물 면역을 활용한 암 치료 |
| JP2021512950A (ja) * | 2018-02-02 | 2021-05-20 | エスエル・ベクシジェン・インコーポレイテッドＳｌ Ｖａｘｉｇｅｎ， Ｉｎｃ． | 新規なワクチンの免疫補助剤 |
| WO2020127222A2 (en) | 2018-12-17 | 2020-06-25 | Immudex Aps | Panel comprising borrelia mhc multimers |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| KR20220038608A (ko) * | 2019-05-31 | 2022-03-29 | 배리에이션 바이오테크놀로지스 아이엔씨. | 다형성 교모세포종의 치료를 위한 면역치료 조성물 |
| CN114466659A (zh) * | 2019-09-09 | 2022-05-10 | 葛兰素史克生物有限公司 | 免疫治疗组合物 |
| JP2023078487A (ja) * | 2020-04-08 | 2023-06-07 | アステラス製薬株式会社 | がんの処置に用いるｐｐ６５含有人工アジュバントベクター細胞 |
| ES2987329T3 (es) | 2020-05-22 | 2024-11-14 | Philogen Spa | Terapia con el inmunoconjugado de TNF-a para el tratamiento de tumores cerebrales |
| TWI871709B (zh) | 2020-06-21 | 2025-02-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽 |
| US20230293673A1 (en) * | 2020-08-06 | 2023-09-21 | La Jolla Institute For Immunology | Methods for treating and preventing cytomegalovirus infection |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| GB2603166A (en) * | 2021-01-29 | 2022-08-03 | Thelper As | Therapeutic and Diagnostic Agents and Uses Thereof |
| US20240226159A9 (en) * | 2021-03-09 | 2024-07-11 | Board Of Regents, The University Of Texas System | Low intensity ultrasound combination cancer therapies |
| CN117257925B (zh) * | 2023-09-20 | 2024-05-28 | 青岛大学 | 基于人巨细胞病毒编码即刻早期蛋白ie的疫苗、其制备方法和应用 |
| CN117169518B (zh) * | 2023-11-03 | 2024-01-19 | 赛德特(北京)生物工程有限公司 | T淋巴细胞制剂中的cd3抗体残留物的检测方法和试剂盒 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| US6207161B1 (en) | 1986-07-16 | 2001-03-27 | City Of Hope | Induction of cytolytic T-lymphocytes with cytomegalovirus polypeptides |
| US4906564A (en) | 1987-03-13 | 1990-03-06 | The United States Of America As Represented By The Secretary Of The Army | Antigenic determinants recognized by antibodies obtained using a pathogenic agent or a derivative thereof that presents a restricted set of antigens |
| AU658836B2 (en) | 1990-09-25 | 1995-05-04 | Xenova Research Limited | Viral defective vaccine produced by transcomplementing cell line |
| AU695584B2 (en) * | 1993-01-28 | 1998-08-20 | Novartis Pharmaceutical Corporation | Human monoclonal antibodies to cytomegalovirus |
| EP0689603A1 (en) | 1993-03-19 | 1996-01-03 | Cantab Pharmaceuticals Research Limited | Defective mutant non-retroviral virus (e.g. hsv) as vaccine |
| US6448389B1 (en) * | 1996-04-23 | 2002-09-10 | The Wistar Institute Of Anatomy And Biology | Human cytomegalovirus DNA constructs and uses therefor |
| US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| US6074645A (en) * | 1996-11-12 | 2000-06-13 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
| US6562345B1 (en) * | 1996-11-12 | 2003-05-13 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
| US6156317A (en) * | 1996-11-12 | 2000-12-05 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
| US6503503B1 (en) | 1997-05-13 | 2003-01-07 | Duke University | Allogeneic cellular vaccine |
| US6013258A (en) | 1997-10-09 | 2000-01-11 | Zycos Inc. | Immunogenic peptides from the HPV E7 protein |
| US6291446B1 (en) | 1998-03-05 | 2001-09-18 | Eli Lilly And Company | Therapeutic treatment for cytomegalovirus infection |
| IL125608A0 (en) | 1998-07-30 | 1999-03-12 | Yeda Res & Dev | Tumor associated antigen peptides and use of same as anti-tumor vaccines |
| AU771946B2 (en) | 1998-08-31 | 2004-04-08 | Oregon Health And Science University | Prevention of cell migration initiation with CMV US28 receptor antagonists |
| US6572856B1 (en) | 1998-09-10 | 2003-06-03 | The University Of Virginia Patent Foundation | Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies |
| US6350451B1 (en) | 1999-06-25 | 2002-02-26 | The Board Of Trustees Of The University Of Arkansas | Immunotherapy of epithelial tumors using intralesional injection of antigens that induce a delayed type hypersensitivity reaction |
| US7005131B1 (en) | 1999-08-13 | 2006-02-28 | The Rockefeller University | Protective antigen of Epstein Barr Virus |
| AU2001240109A1 (en) | 2000-03-07 | 2001-09-17 | U.S. Army Medical Research Institute Of Infectious Diseases | Dna vaccines against poxviruses |
| JP2003527847A (ja) | 2000-03-21 | 2003-09-24 | ジェンザイム・コーポレーション | 治療用抗サイトメガロウイルス化合物 |
| EP1146119A1 (en) * | 2000-04-12 | 2001-10-17 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for obtaining specific T-lymphocytes, and for identifying unknown epitopes |
| US7025968B2 (en) * | 2000-08-30 | 2006-04-11 | Chemocentryx, Inc. | CMV vaccines |
| US20040241140A1 (en) | 2000-11-01 | 2004-12-02 | Pavlakis George N. | Expression vectors able to elicit improved immune response and methods of using same |
| CA2437201C (en) | 2001-02-02 | 2008-11-18 | Chemocentryx, Inc. | Methods and compositions useful for stimulating an immune response |
| AUPR395801A0 (en) | 2001-03-26 | 2001-04-26 | Austin Research Institute, The | Antibodies against cancer |
| AUPR593101A0 (en) * | 2001-06-26 | 2001-07-19 | Council Of The Queensland Institute Of Medical Research, The | Cytomegalovirus t cell epitopes |
| WO2004023091A2 (en) | 2002-09-03 | 2004-03-18 | The Uab Research Foundation | Localization of human cytomegalovirus nucleic acids and proteins in human cancer cells |
| US7740871B2 (en) | 2002-09-19 | 2010-06-22 | Johns Hopkins University School Of Medicine | Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine |
| EP1408106B1 (en) | 2002-10-11 | 2007-02-14 | Sentoclone Therapeutics AB | Cancer immuno-therapy |
| WO2004053095A2 (en) | 2002-12-10 | 2004-06-24 | Merix Bioscience, Inc. | In situ maturation of dendritic cells |
| WO2004058166A2 (en) * | 2002-12-23 | 2004-07-15 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
| US7163685B2 (en) | 2003-04-16 | 2007-01-16 | City Of Hope | Human cytomegalovirus antigens expressed in MVA and methods of use |
| US20050232933A1 (en) * | 2003-09-30 | 2005-10-20 | Zaia John A | CMV-IE1 peptides and method of use |
| WO2006056027A1 (en) * | 2004-11-29 | 2006-06-01 | The Council Of The Queensland Institute Of Medical Research | Human cytomegalovirus immunotherapy |
| WO2007130470A2 (en) * | 2006-05-01 | 2007-11-15 | The Regents Of The University Of California | Cytomegalovirus peptides and methods of use thereof |
| WO2008039969A2 (en) | 2006-09-28 | 2008-04-03 | Cedars-Sinai Medical Center | Cancer vaccines and vaccination methods |
| US8435510B2 (en) * | 2007-08-08 | 2013-05-07 | Sutter West Bay Hospitals | Platelet derived growth factor receptor supports cytomegalovirus infectivity |
| CA2728739C (en) * | 2008-06-20 | 2017-07-11 | Duke University | Use of human cytomegalovirus antigens to enhance immune responses to cancer cells |
| CN102076354A (zh) | 2008-07-03 | 2011-05-25 | 杜克大学 | 用于引发免疫应答的组合物和方法 |
| WO2015073801A1 (en) * | 2013-11-14 | 2015-05-21 | Duke University | Tetanus toxoid and ccl3 improve dc vaccines |
-
2009
- 2009-06-19 CA CA2728739A patent/CA2728739C/en active Active
- 2009-06-19 DK DK16184921.1T patent/DK3156069T3/da active
- 2009-06-19 US US12/488,176 patent/US8425898B2/en active Active
- 2009-06-19 EP EP22202748.4A patent/EP4218806A1/en not_active Withdrawn
- 2009-06-19 EP EP16184921.1A patent/EP3156069B8/en active Active
- 2009-06-19 AU AU2009259923A patent/AU2009259923B2/en active Active
- 2009-06-19 WO PCT/US2009/047987 patent/WO2009155535A2/en not_active Ceased
- 2009-06-19 JP JP2011514851A patent/JP2011525191A/ja active Pending
- 2009-06-19 CN CN2009801288723A patent/CN102123732A/zh active Pending
- 2009-06-19 EP EP20181935.6A patent/EP3766517B1/en active Active
- 2009-06-19 EP EP09767844.5A patent/EP2303319B1/en active Active
-
2013
- 2013-01-23 US US13/748,096 patent/US9011835B2/en active Active
-
2015
- 2015-01-30 JP JP2015016782A patent/JP2015134767A/ja active Pending
- 2015-04-08 US US14/681,534 patent/US9764026B2/en active Active
-
2016
- 2016-12-22 JP JP2016249706A patent/JP6342982B2/ja active Active
-
2017
- 2017-08-14 US US15/676,330 patent/US10632190B2/en not_active Expired - Fee Related
-
2020
- 2020-03-18 US US16/822,354 patent/US11389530B2/en active Active
- 2020-07-22 US US16/935,813 patent/US11351248B2/en active Active
- 2020-07-23 US US16/937,171 patent/US11364295B2/en active Active
- 2020-07-24 US US16/937,801 patent/US11376322B2/en active Active
-
2022
- 2022-05-06 US US17/738,576 patent/US20220370602A1/en not_active Abandoned
- 2022-05-17 US US17/746,329 patent/US20220387582A1/en not_active Abandoned
- 2022-05-31 US US17/828,554 patent/US12070496B2/en active Active
- 2022-06-15 US US17/841,140 patent/US20220401552A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wu et al. | The mucosal immune system in the oral cavity—an orchestra of T cell diversity | |
| JP2023052777A5 (enExample) | ||
| Ray et al. | Regulatory T cells in many flavors control asthma | |
| Durward et al. | Active evasion of CTL mediated killing and low quality responding CD8+ T cells contribute to persistence of brucellosis | |
| Reilly et al. | Activated i NKT Cells Promote Memory CD8+ T Cell Differentiation during Viral Infection | |
| JP2012526853A5 (enExample) | ||
| JP2020528911A5 (enExample) | ||
| JP2016513115A5 (enExample) | ||
| EP2385059A3 (en) | Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma | |
| GB2434367A (en) | Improved vaccines | |
| Dong et al. | Incorporation of CD40 ligand or granulocyte-macrophage colony stimulating factor into Hantaan virus (HTNV) virus-like particles significantly enhances the long-term immunity potency against HTNV infection | |
| WO2012116225A3 (en) | Muc1 based glycolipopeptide vaccine with adjuvant | |
| WO2009114085A3 (en) | Allogeneic cancer cell-based immunotherapy | |
| EA200701128A1 (ru) | Рекомбинантные штаммы bcg, обладающие повышенной способностью к высвобождению из эндосомы | |
| HRP20150177T1 (hr) | Cjepivo protiv tuberkuloze i postupak upotrebe tog cjepiva | |
| RU2015101110A (ru) | Вакцинные композиции с катионными липидами и способы применения | |
| JP2010532656A5 (enExample) | ||
| Singh et al. | Manipulation of BCG vaccine: a double-edged sword | |
| JP2015526469A5 (enExample) | ||
| EA201790365A1 (ru) | Антигены вируса папилломы человека с хорошими иммунологическими свойствами и содержащая их вакцина | |
| JP2013504600A5 (enExample) | ||
| Aggarwal et al. | Cellular T-cell immune response profiling by tetravalent dengue subunit vaccine (DSV4) candidate in mice | |
| JP2014009272A5 (enExample) | ||
| RU2013143741A (ru) | Терапевтическая вакцина против рака | |
| JP2008286529A5 (enExample) |